{"id":3166,"date":"2019-09-19T13:10:50","date_gmt":"2019-09-19T13:10:50","guid":{"rendered":"http:\/\/www.enyopharma.com\/fr\/?p=3166"},"modified":"2019-10-03T13:38:34","modified_gmt":"2019-10-03T13:38:34","slug":"enyo-pharma-annonce-le-recrutement-dun-nouveau-directeur-financier-et-actualise-son-pipeline-clinique","status":"publish","type":"post","link":"https:\/\/www.enyopharma.com\/fr\/enyo-pharma-annonce-le-recrutement-dun-nouveau-directeur-financier-et-actualise-son-pipeline-clinique\/","title":{"rendered":"ENYO PHARMA ANNONCE LE RECRUTEMENT D\u2019UN NOUVEAU DIRECTEUR FINANCIER ET ACTUALISE SON PIPELINE CLINIQUE"},"content":{"rendered":"<p>Lyon, France, le 19 Septembre 2019 &#8211; Â鶹Æƽâ°æ, une soci\u00e9t\u00e9 priv\u00e9e de biotechnologie au stade clinique d\u00e9veloppant des candidats m\u00e9dicaments innovants, a annonc\u00e9 aujourd&#8217;hui la nomination de Jonathan Lieber au poste de directeur financier. Â鶹Æƽâ°æ a \u00e9galement fourni aujourd\u2019hui une mise \u00e0 jour du pipeline mettant l\u2019accent sur EYP001 (Vonafexor, proposition de l\u2019INN), un agoniste de FXR actuellement en phase II de d\u00e9veloppement clinique pour le traitement de l\u2019h\u00e9patite B (VHB) et de la st\u00e9atose h\u00e9patique non alcoolique (NASH).<\/p>\n <a href=\"http:\/\/www.enyopharma.com\/wp-content\/uploads\/2019\/09\/Enyo-CFO-change-and-pipeline-update-FR.pdf\" target=\"_blank\" rel=\"noopener\" target=\"_blank\" class=\"tano-file\"><span class=\"tano_download_icon\"><\/span><span class=\"tano_file_title\">T\u00e9l\u00e9charger le communiquer complet (PDF)<\/span><\/a> \n","protected":false},"excerpt":{"rendered":"<p>Lyon, France, le 19 Septembre 2019 &#8211; Â鶹Æƽâ°æ, une soci\u00e9t\u00e9 priv\u00e9e de biotechnologie au stade clinique d\u00e9veloppant des candidats m\u00e9dicaments innovants, a annonc\u00e9 aujourd&#8217;hui la nomination de Jonathan Lieber au poste de directeur financier. Â鶹Æƽâ°æ a \u00e9galement fourni aujourd\u2019hui une mise \u00e0 jour du pipeline mettant l\u2019accent sur EYP001 (Vonafexor, proposition de l\u2019INN), un agoniste de FXR actuellement en phase II de d\u00e9veloppement clinique pour le traitement de l\u2019h\u00e9patite B (VHB) et de la st\u00e9atose h\u00e9patique non alcoolique (NASH).<\/p>\n<p><a class=\"read-more\" href=\"https:\/\/www.enyopharma.com\/fr\/enyo-pharma-annonce-le-recrutement-dun-nouveau-directeur-financier-et-actualise-son-pipeline-clinique\/\">Lire la suite&nbsp;&raquo;<\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[17],"tags":[],"class_list":["post-3166","post","type-post","status-publish","format-standard","hentry","category-press-releases-fr"],"acf":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","rttpg_featured_image_url":null,"rttpg_author":{"display_name":"editorENYOPharma","author_link":"https:\/\/www.enyopharma.com\/fr\/author\/editorenyopharma\/"},"rttpg_comment":0,"rttpg_category":"<a href=\"https:\/\/www.enyopharma.com\/fr\/category\/press-releases-fr\/\" rel=\"category tag\">Press releases<\/a>","rttpg_excerpt":"Lyon, France, le 19 Septembre 2019 &#8211; Â鶹Æƽâ°æ, une soci\u00e9t\u00e9 priv\u00e9e de biotechnologie au stade clinique d\u00e9veloppant des candidats m\u00e9dicaments innovants, a annonc\u00e9 aujourd&#8217;hui la nomination de Jonathan Lieber au poste de directeur financier. Â鶹Æƽâ°æ a \u00e9galement fourni aujourd\u2019hui une mise \u00e0 jour du pipeline mettant l\u2019accent sur EYP001 (Vonafexor, proposition de l\u2019INN),&hellip;","_links":{"self":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/3166","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/comments?post=3166"}],"version-history":[{"count":2,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/3166\/revisions"}],"predecessor-version":[{"id":3216,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/3166\/revisions\/3216"}],"wp:attachment":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/media?parent=3166"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/categories?post=3166"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/tags?post=3166"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}